Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“I had to enlist ChatGPT to help me write a victory-winning poem rebuttal to Corey Langer’s debate argument that lurbinectedin maintenance and tarlatamab for 2L SCLC are treatments for the average patient and not the select fit patients who can tolerate chemo maintenance, CRS, ICANS and cost of these drugs.”
More posts featuring Estela Rodriguez.
